InvestorNewsBreaks – Tryp Therapeutics Inc. (CSE: TRYP) (OTCQB: TRYPF) Appoints Veteran Finance Exec as CFO
Sep 19, 2022
Tryp Therapeutics (CSE: TRYP) (OTCQB: TRYPF), a clinical-stage biotechnology company focused on developing psilocybin-based compounds for diseases with unmet medical needs, today announced that it has expanded its leadership team with the appointment of Jim O’Neill as its chief financial officer. In the new role, O’Neill, who brings over 30 years of experience as a finance executive with publicly listed and private multinational businesses, will oversee all aspects of Tryp’s finance and accounting organization. O’Neill’s appointment follows the planned transition of Sid Taubenfeld from interim chief financial officer to his current role as chief operating officer. “We are excited to welcome Jim to our senior executive team and look forward to leveraging his extensive experience to continue growing our company,” said Jim Gilligan, CEO of Tryp Therapeutics. “Jim’s appointment as CFO demonstrates our continued commitment to establishing Tryp as a leading developer of revolutionary psychedelic drugs for the treatment of unique and under targeted indications. We believe his extensive financial expertise and public company experience make him an ideal addition to our team.”
To view the full press release, visit https://ibn.fm/AyMnb
About Tryp Therapeutics Inc.
Tryp Therapeutics is a clinical-stage biotechnology company focused on developing psilocybin-related molecules, including TRP-8803, for the treatment of diseases with unmet medical needs through accelerated regulatory pathways. Tryp’s Psilocybin-for-Neuropsychiatric Disorders (“PFN”(TM)) program is focused on the development of synthetic psilocybin-related molecules as a new class of drug for the treatment of binge eating, chronic pain and other indications. The company has begun enrolling patients in its phase II trial for the treatment of binge eating disorder at the University of Florida and recently announced an upcoming phase IIa clinical trial with the University of Michigan to evaluate TRP-8802 for fibromyalgia. TRP-8803 is a proprietary psilocybin-based product that uses a novel formulation and route of administration to potentially improve efficacy, safety and the patient experience. For more information, please visit www.TrypTherapeutics.com.
NOTE TO INVESTORS: The latest news and updates relating to TRYPF are available in the company’s newsroom at https://ibn.fm/TRYPF
About InvestorWire
InvestorWire is the wire service that gives you more. From regional releases to global announcements presented in multiple languages, we offer the wire-grade dissemination products you’ll need to ensure that your next press release grabs the attention of your target audience and doesn’t let go. While our competitors look to nickel and dime you with hidden fees and restrictive word limits, InvestorWire keeps things transparent.
As part of its service, InvestorWire provides coverage of noteworthy announcements. To further expand visibility of achievements being made throughout a multitude of sectors, InvestorWire’s syndication partners have extended the digital coverage to include individual broadcasts on financial websites and platforms visited by millions of investors daily.
For more information, please visit https://www.InvestorWire.com
Please see full terms of use and disclaimers on the InvestorBrandNetwork website applicable to all content provided by IBN, wherever published or re-published: http://ibn.fm/Disclaimer
InvestorWire (IW)
8033 Sunset Blvd Suite 1037-IW
Los Angeles, CA 90046
310.299.1717 Office
www.InvestorWire.com
[email protected]
InvestorWire is part of the InvestorBrandNetwork.
More News
Rosebank: Life on the oil field at the centre of a political storm
Scotland editor James Cook finds out what life is like on board a ship in an untapped oil field awaiting its fate.
Heating oil costs 'more than double' ahead of winter
Middleton in Teesdale has no mains gas supply so many residents use expensive heating oil.
How families are cutting the cost of Halloween as spending grows
Families are turning to homemade costumes, swaps and second-hand outfits to keep it affordable.
Firms 'holding back' on new jobs ahead of Budget
Some businesses say they want to see employment costs come down in the October Budget.
Will a new code end 'rip-off parking charges'?
The prime minister says a new code will end "rip-off parking charges" - but will it work?
Budget 2026: No more fat to trim for 'squeezed middle'
As the chancellor finalises his first Budget, how are the "squeezed middle" feeling about costs?
Four ways Labour could raise money in the Budget without hiking income tax
Chancellor John Healey may need to raise money to boost his fiscal headroom - BBC Verify examines what options could be on the table.
For Clues About How A.I. Will Change Work, Look to the Past
Economists hope earlier episodes of labor disruption, from the Industrial Revolution to the Great Depression, can help us prepare for the age of artificial intelligence.
Six Flags to Add Seatbelts on Roller Coasters After Rider’s Death
The company said that all Six Flags rides and attractions would undergo safety reviews, as the park operator faces lawsuits over safety concerns.
Attention, Passengers: High Airfares May Be Here to Stay
Ticket prices jumped after fuel costs spiked because of the war with Iran, but airlines say even an end to the conflict will not bring fares back down quickly.
5 Takeaways From Our Investigation of Trump’s Waivers for Polluters
Chemical plants and other industrial facilities had been required to curb their toxic emissions. A New York Times investigation shows how they got out of it.
Rising demand from families needing Christmas help
Charlotte Riley says more families are reaching out for help for a variety of reasons.
YOUR NEWS, OUR NETWORK.
Do you have Great News you want to tell the world?
Be it updates about your business or your community, you can make sure that it’s heard by submitting your story to our network reaching hundreds of news sites across 6 verticals.